James Oliviero
Chief Executive Officer bei CHECKPOINT THERAPEUTICS, INC.
Vermögen: 928 839 $ am 31.03.2024
Profil
James F.
Oliviero is currently the President, Chief Executive Officer & Director at Checkpoint Therapeutics, Inc. He is also an Independent Director at Nuvectis Pharma, Inc. Previously, he served as the Finance Director at ACCESS Oncology, Inc. from 1999 to 2003.
He then worked as the Chief Financial Officer & Treasurer at Keryx Biopharmaceuticals, Inc. from 2003 to 2015.
Mr. Oliviero completed his undergraduate degree at Goizueta Business School-Emory.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 19.03.2024 | 341 780 ( 1,50% ) | 700 649 $ | 31.03.2024 | |
NUVECTIS PHARMA, INC.
0,16% | 16.06.2023 | 27 828 ( 0,16% ) | 228 190 $ | 31.03.2024 |
Aktive Positionen von James Oliviero
| Unternehmen | Position | Beginn |
|---|---|---|
| CHECKPOINT THERAPEUTICS, INC. | Chief Executive Officer | 13.10.2015 |
| NUVECTIS PHARMA, INC. | Director/Board Member | 01.07.2021 |
Ehemalige bekannte Positionen von James Oliviero
| Unternehmen | Position | Ende |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Director of Finance/CFO | 01.09.2015 |
ACCESS Oncology, Inc.
 ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a private company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Director of Finance/CFO | 01.05.2003 |
Ausbildung von James Oliviero
| Goizueta Business School-Emory | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CHECKPOINT THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Keryx Biopharmaceuticals, Inc.
 Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA. | Health Technology |
ACCESS Oncology, Inc.
ACCESS Oncology, Inc. Pharmaceuticals: OtherHealth Technology Part of Akebia Therapeutics, Inc., ACCESS Oncology, Inc. is a private company that develops pharmaceutical drugs. The company is based in New York, NY. The company was founded by Michael Sean Weiss. ACCESS Oncology was acquired by Keryx Biopharmaceuticals, Inc., part of Akebia Therapeutics, Inc. from December 13, 2018 on February 06, 2004 for $36.44 million. | Health Technology |
| Nuvectis Pharma, Inc. |
